Mauna Kea Technologies and Tasly Pharmaceuticals form joint venture for Cellvizio in China and neurology

Mauna Kea Technologies and Tasly Pharmaceuticals formed a joint venture to develop, manufacture and commercialize Cellvizio in China and globally for neurology and neurosurgery. Mauna Kea will receive $10 million in cash, a 44.1% equity stake, and a 5-year purchase commitment.

“We are delighted to partner with Tasly Pharmaceuticals, a life sciences leader in Asia-Pacific with a global presence.”maunakeatech.com

• 1 source
• maunakeatech.comTasly Pharmaceuticals and Mauna Kea Technologies Announce Joint Venture and Licensing Agreements - Mauna Kea TechnologiesZinaJul 11, 2022

Summarized from public sources; check the original articles before acting on it.